JanOne Inc.

    Jurisdiction
    United States
    LEI
    549300FLMHTQ5MK4YD23
    ISIN
    US47089W1045 (JAN)
    Sectors
    1. Industrials
    2. Waste Management

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    1 / 7

    Profile

    JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. Read full profile

    Fundamentals

    Net revenue
    €22.68M
    Gross margin
    53.2%
    EBIT
    -€10.61M
    EBIT margin
    -46.8%
    Net income
    -€891.33K
    Net margin
    -3.9%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.06
    Ex date
    Payment date

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 92K $357.61K +70K Buy

    Earnings Calls

    Latest earnings call: November 4, 2014 (Q3 2014)

    Add to watchlist

    Notifications